UCB Grabs Candid’s BCMA T-Cell Engager – Here’s Why CGEM Investors Are Celebrating
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
/ 5 items
#CGEM↓
Clear Street: Gilead Deal Highlights Huge Potential in Cullinan’s Pipeline
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.
Cullinan Therapeutics Gets Buy Rating from Citi
Citi gave Cullinan Therapeutics a Buy rating with a $33 target, citing its cancer/autoimmune drug pipeline and key 2026 data readouts as a strong risk/reward opportunity.
Guggenheim Initiates Buy on Cullinan Therapeutics with $30 Target
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.